Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 12/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.66 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775861 | 0.88 | PIK3CA (0.56) | MTORPIK3CAUSP7LMNAGLA | |
| SCHEMBL752472 | 0.81 | PIK3CA (0.54) | MTORPIK3CACCNE1CDK2KDM4E | |
| SCHEMBL2773726 | 0.80 | PIK3CA (0.51) | MTORPIK3CACCNE1CDK2KDM4E | |
| SCHEMBL2787610 | 0.80 | MTOR (1.00) | MTORPIK3CAUSP7LMNAGLA | |
| SCHEMBL2772137 | 0.79 | PIK3CA (0.54) | MTORPIK3CACCNE1CDK2KDM4E | |
| SCHEMBL752556 | 0.79 | MTOR (0.72) | MTORPIK3CAUSP7LMNAGLA | |
| SCHEMBL2790005 | 0.79 | PIK3CA (0.62) | MTORPIK3CACCNE1CDK2NPSR1 | |
| SCHEMBL11028397 | 0.78 | PIK3CA (0.59) | MTORPIK3CAUSP7LMNAGLA | |
| SCHEMBL751862 | 0.78 | PIK3CA (0.56) | MTORPIK3CAKDM4ENPSR1HSD17B10 | |
| SCHEMBL2771022 | 0.76 | PIK3CA (0.62) | MTORPIK3CAUSP7CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | MTOR 21/4885PIK3CA 1/4885USP7 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.